Moxquin XG0.5%+0.4%

Indications

Moxquin XG ophthalmic solution is a topical fluoroquinolone antibiotic combined with xanthan gum, a viscosity-enhancing (mucoadhesive) agent that prolongs contact time of the drug on the ocular surface. It is indicated for the following:

• Established/FDA-approved use: Treatment of bacterial conjunctivitis (pink eye) caused by susceptible strains of bacteria, including certain Gram-positive organisms (e.g., Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, other streptococci) and Gram-negative organisms (e.g., Haemophilus influenzae).
• Guideline-supported/perioperative use: Some ophthalmologists use Moxquin XG off-label around the time of intraocular surgery (e.g., cataract surgery) to reduce the bacterial load on the ocular surface and lower the risk of postoperative endophthalmitis, in line with general fluoroquinolone perioperative prophylaxis practice; this is not a formally labeled indication for every product in this class and should follow the treating ophthalmologist's protocol.

Moxquin XG is not indicated for viral, fungal, or mycobacterial eye infections, and it does not treat systemic (whole-body) infections when applied to the eye.

Each formulation of Moxifloxacin Hydrochloride + Xanthan Gum ophthalmic solution typically contains moxifloxacin hydrochloride equivalent to 0.5% moxifloxacin base as the active antibacterial ingredient, combined with xanthan gum as an inactive, viscosity-enhancing excipient. The xanthan gum forms a gel-like matrix on contact with the tear film, increasing the residence time of moxifloxacin on the eye surface. Other inactive ingredients commonly included are boric acid, sodium chloride, and purified water, with pH adjusted using sodium hydroxide and/or hydrochloric acid as needed.

Moxquin XG is a sterile, preservative-containing (or preservative-free, depending on the specific brand) ophthalmic solution combining a fourth-generation fluoroquinolone antibiotic (moxifloxacin hydrochloride) with xanthan gum, a naturally derived polysaccharide used as a viscosity-modifying agent. The xanthan gum component thickens on contact with the eye, prolonging the contact time of moxifloxacin with the ocular surface compared with conventional aqueous eye drops. This formulation characteristic is why some brands of Moxquin XG are dosed less frequently (e.g., twice daily) than standard moxifloxacin eye drops without xanthan gum. Moxquin XG is applied topically to the eye and is used specifically for bacterial infections of the conjunctiva.

Moxquin XG belongs to the therapeutic class of ophthalmic fluoroquinolone antibacterial agents, used for the topical treatment of susceptible bacterial eye infections.

Pharmacology

Moxifloxacin Hydrochloride + Xanthan Gum exerts its antibacterial effect through moxifloxacin, an 8-methoxyfluoroquinolone that inhibits two essential bacterial enzymes: DNA gyrase (topoisomerase II) and topoisomerase IV. By blocking these enzymes, moxifloxacin prevents bacterial DNA replication, transcription, repair, and recombination, leading to bactericidal activity against a broad range of Gram-positive and Gram-negative organisms commonly implicated in bacterial conjunctivitis.

The xanthan gum component of Moxifloxacin Hydrochloride + Xanthan Gum is not antibacterial itself; it is a high-molecular-weight polysaccharide that increases the viscosity of the solution upon instillation, forming a gel-like film that adheres to the ocular surface. This prolongs the contact time between moxifloxacin and the conjunctiva/cornea, which can allow for less frequent dosing while maintaining effective local drug concentrations. Systemic absorption after topical ocular administration of Moxifloxacin Hydrochloride + Xanthan Gum is minimal.

Administration Instructions

• Wash hands thoroughly before use.
• Tilt the head back slightly and gently pull down the lower eyelid to form a small pocket.
• Invert the Moxquin XG bottle and instill one drop into the pocket without letting the dropper tip touch the eye, eyelid, or any surface, to avoid contamination.
• Close the eye gently for 1–2 minutes and apply light pressure at the inner corner of the eye (near the nose) to reduce systemic drainage.
• If more than one eye drop product is being used, wait at least 5 minutes between different eye medications.
• Do not touch the tip of the applicator to any surface, and replace the cap immediately after use.
• Remove contact lenses before use if signs and symptoms of bacterial conjunctivitis are present; do not resume lens wear until the infection has resolved and the physician approves.

Drug Interactions

Because Moxquin XG is applied topically to the eye, systemic absorption is minimal and clinically significant drug-drug interactions are uncommon compared with oral or intravenous fluoroquinolones. However:

• If other topical ophthalmic medications are being used concurrently, they should be administered at least 5 minutes apart from Moxquin XG to prevent one product from washing out or diluting another.
• Concomitant use with other ophthalmic products containing corticosteroids may mask or delay recognition of a worsening infection; such combinations should only be used under close physician supervision.
• No clinically significant systemic drug interactions (e.g., with warfarin, antacids, or QT-prolonging agents, which are relevant for oral/IV moxifloxacin) have been established for the topical ophthalmic route at recommended doses of Moxquin XG.

Side Effects

Most side effects of Moxquin XG are mild, local, and transient. Reported adverse effects include:

• Eye irritation or burning/stinging on instillation
• Temporary blurred vision immediately after application, related to the increased viscosity from the xanthan gum vehicle (this typically resolves within a few minutes)
• Dry eye sensation
• Conjunctival redness or hyperemia
• Eye pain or discomfort
• Itching (pruritus) of the eye
• Headache
• Decreased or blurred visual acuity (usually transient)

Rare but serious reactions can include hypersensitivity/allergic reactions (swelling, rash, itching, difficulty breathing) — see Precautions and Warnings. Patients should contact their physician if symptoms worsen or do not improve within a few days of starting Moxquin XG.

Pregnancy and Lactation

There are no adequate and well-controlled studies of Moxquin XG in pregnant women. Although systemic absorption after ophthalmic administration is minimal, Moxquin XG should be used during pregnancy only if the potential benefit to the mother justifies the potential (though likely low) risk to the fetus, and only after consultation with a physician.

It is not known whether topically applied Moxquin XG is excreted in human breast milk in clinically significant amounts. Because many drugs are excreted in breast milk, caution should be exercised, and a physician should be consulted before using Moxquin XG while breastfeeding.

Precautions and Warnings

• Hypersensitivity reactions: Serious hypersensitivity reactions, some following the first dose, have been reported with fluoroquinolones (including systemic formulations); discontinue Moxquin XG at the first sign of a rash, allergic reaction, or other hypersensitivity symptom and seek medical attention.
• Contact lens wear: Patients should not wear contact lenses if they have signs or symptoms of bacterial conjunctivitis, or during the course of treatment with Moxquin XG, and should not resume lens wear until the infection has fully resolved and their physician has confirmed it is safe to do so.
• Temporary blurred vision: Due to the increased viscosity of the xanthan gum vehicle, transient blurred vision may occur immediately after instillation. Patients should wait until vision clears before driving, operating machinery, or performing other tasks requiring clear eyesight.
• Growth of resistant organisms/superinfection: As with other antibacterial products, prolonged use of Moxquin XG may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, discontinue use and institute alternative therapy.
• Not for injection: Moxquin XG is for topical ophthalmic use only and must not be injected into the eye or used intraocularly.
• Fluoroquinolone class effects: Systemic fluoroquinolones have been associated with tendon rupture, peripheral neuropathy, and central nervous system effects; these risks are generally not considered clinically relevant at the very low systemic exposure achieved with ophthalmic Moxquin XG, but general class awareness is advised, particularly with prolonged or off-label use beyond the eye.
• Stewardship: Use Moxquin XG exactly as prescribed for the full course; do not stop, extend, skip doses, or share this medicine with others without medical advice.

Overdose

Topical ocular overdose of Moxquin XG is unlikely to cause serious systemic toxicity given minimal systemic absorption. If excessive drops are instilled, the eye may be flushed with lukewarm water. If Moxquin XG is accidentally ingested (swallowed) or splashed into the eyes in large amounts, or if any concerning symptoms develop, seek immediate medical attention or contact a poison control center/emergency services rather than attempting home treatment.

Store Moxquin XG at room temperature (below 30°C), away from light and moisture. Do not freeze. Keep the bottle tightly closed when not in use, discard any unused solution after the period specified on the label (commonly 28 days after opening), and keep out of reach of children.

Use in Special Populations

• Pediatric use: Safety and efficacy of Moxquin XG have been established in children 4 months of age and older for bacterial conjunctivitis. Safety and efficacy in infants younger than 4 months have not been established.
• Geriatric use: No overall differences in safety or effectiveness have been observed between elderly and younger adult patients; no dose adjustment is required based on age alone.
• Renal/hepatic impairment: Given the minimal systemic absorption with topical ophthalmic use, no dose adjustment is established or generally required in patients with renal or hepatic impairment.
• Pregnancy and lactation: See Pregnancy and Lactation section above for detailed guidance.

The typical duration of treatment with Moxquin XG for bacterial conjunctivitis is 7 days. The full prescribed course should be completed even if symptoms improve earlier, unless the treating physician advises otherwise.

Moxifloxacin Hydrochloride + Xanthan Gum belongs to the fluoroquinolone antibiotic class, specifically formulated as an ophthalmic (topical eye) antibacterial combined with a viscosity-enhancing agent (xanthan gum).

Moxifloxacin Hydrochloride + Xanthan Gum works by moxifloxacin inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, and repair; this action is bactericidal against susceptible organisms causing conjunctival infection. The xanthan gum component increases the viscosity of the solution on contact with the eye, prolonging the residence time of moxifloxacin on the ocular surface and supporting sustained antibacterial activity between doses.

C

Pediatric Use

Moxquin XG is approved for use in children 4 months of age and older for the treatment of bacterial conjunctivitis, at the same dosing as adults (one drop in the affected eye(s) as directed by the physician). Safety and efficacy in infants younger than 4 months of age have not been established, and use in this age group should only occur under close specialist supervision if the potential benefit outweighs the uncertainty. As with adults, the medication should be used for the complete prescribed duration and not shared with other children.